Fig. 2.
Kaplan-Meier curves showing overall survival (OS) (A) and progression-free survival (PFS) (B) according to the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. Patients with the methylated MGMT promoter had a longer OS (23.9 months vs. 16.7 months) and longer PFS (13.2 months vs. 9.3 months) than those with the unmethylated MGMT promoter.